Drug Trial Radar · NCT06551181
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,620
Actual
Start
Aug 5, 2024
Primary completion
Apr 24, 2025
Study completion Sep 15, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (\>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled from overseas countries that participated in the RSV OA=ADJ-006 (NCT04886596) study, since the vaccine efficacy against lower respiratory tract disease (LRTD) has been demonstrated following a single dose of the RSVPreF3 OA investigational vaccine in the global efficacy study RSV OA=ADJ-006. In addition, the safety (in all participants) , reactogenicity and occurrence of RSV-associated acute respiratory illness (ARI) (in study participants in China only) after administration of the vaccine are also assessed in the current study. No ARI surveillance will be conducted for the overseas participants.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccineBiological
One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.
Placebo (Saline solution)Drug
One dose of placebo is administered intramuscularly at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31
- Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31 compared to baseline (Day 1)
- RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31
- Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31 compared to baseline (Day 1)
Locations
40 sites in 7 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, Putuo, China
GSK Investigational Site
Shanghai, Putuo, China
GSK Investigational Site
Shanghai, Shanghai Municipality, China
GSK Investigational Site
Espoo, Finland
GSK Investigational Site
Helsinki, Finland
GSK Investigational Site
Kokkola, Finland
GSK Investigational Site
Oulu, Finland
GSK Investigational Site
Seinäjoki, Finland
GSK Investigational Site
Tampere, Finland
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Elblag, Poland
GSK Investigational Site
Katowice, Poland
GSK Investigational Site
Katowice, Poland
GSK Investigational Site
Krakow, Poland
GSK Investigational Site
Lodz, Poland
GSK Investigational Site
Lublin, Poland
GSK Investigational Site
Sochaczew, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Wroclaw, Poland
GSK Investigational Site
Guri-si, South Korea
GSK Investigational Site
Incheon, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Ávila, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Burgos, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Salamanca, Spain
GSK Investigational Site
Valladolid, Spain
GSK Investigational Site
Belfast, United Kingdom
GSK Investigational Site
Blackpool, United Kingdom
GSK Investigational Site
Bristol, United Kingdom
GSK Investigational Site
Cambridgeshire, United Kingdom
GSK Investigational Site
Hounslow, United Kingdom
GSK Investigational Site
Witney, United Kingdom
GSK Investigational Site
Witney, Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.